The Story Behind Growblox Sciences Inc (OTCMKTS:GBLX)

The Story Behind Growblox Sciences Inc (OTCMKTS:GBLX)


Growblox Sciences Inc (OTCMKTS:GBLX) is a micro-cap player in the biotechnology side of the medical marijuana space. The stock has acted poorly overall, rallying into the November vote on legalization across nine states, but promptly giving up all gains in the aftermath. We’ve seen a small bounce in recent days, ostensibly spurred by the company’s announcement that it has engaged CFN Media to conduct a four-month investor and market visibility program beginning on December 15, 2016 on the heels of an IP acquisition.

“GB Sciences has become a biopharmaceutical grade cultivator and leader in developing cannabinoid-based therapies targeting a range of medical conditions,” said Frank Lane, President of CFN Media. “With the licensing of a key patent from Makai Biotechnology, the company has acquired a promising therapeutic targeting heart disease. We are excited to work with the company to develop a broader shareholder audience and unlocking the inherent value in its stock.”

Growblox Sciences Inc (OTCMKTS:GBLX) is a Las Vegas-based firm that frames itself as a company that focuses on the research and development of medical cannabis drugs and treatments.

The company claims to produce measurable medical-grade cannabis, cannabis concentrates, and cannabinoid therapies through using various technologies in plant biology, cultivation, and extraction techniques combined with biotechnology.

It also claims to be involved in the development of controlled-climate indoor agricultural technology growing and cultivation suites, including TissueBLOX, GrowBLOX, CureBLOX, and ExtractionLAB.

According to company materials, “GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on cultivation as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions.”

Find out when $GBLX stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Generally speaking, we’re all for investor awareness when there’s some real meat to the story. The key with this stock will be answering that question. Hiring someone like the folks at CFN is a good move if you have key points to make.

One key point that will surely become a focus soon is the company’s recent announcement that its wholly-owned subsidiary, Growblox Life Sciences, LLC has licensed intellectual property from Makai Biotechnology, LLC.

The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.

GB Sciences CEO, John Poss, remarked: “This license is an important step in our Company’s march to successful drug discovery.  We are very proud of Dr. Small-Howard and her team, and we expect results from this effort that will enable the company to do well by doing good for literally millions of cardiac patients around the world.”

The chart shows 14% piled on for shareholders of the stock during the trailing week. Market participants may want to pay attention to this stock. GBLX is a stock who’s past is littered with sudden rips. Furthermore, the listing has benefitted from a jump in recent trading volume to the tune of 44% above the average volume levels in play in this stock over the longer term.

With that type of expanding volume, we would point out the float on this stock as more than a bit relevant to market outcomes over the near term. This thing is tiny: 6.6M shares. It can be flicked around by the flows quite easily. And flows are picking up. Keep that in mind if shorting the stock.

At this time, carrying a capital value in the market of $23.2M, GBLX has a somewhat surprising reserve ($2.1M) of cash on the books (audited), which stands against about $786K in total current liabilities. The company is pre-revenue at this point. And there is a lot left of this story to be told. This is an exciting possibility, especially with all that cash, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $GBLX stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Sign Up for our 100% FREE Oracle Dispatch Newsletter